Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%

Antiviral Research

Volumn 43, Issue 1, 1999, Pages 55-63

  Arany, Istvan ^a   Tyring, Stephen K ^a   Stanley, Margaret A ^b   Tomai, Mark A ^c   Miller, Richard L ^c   Smith, Michael H ^c   McDermott, Daniel J ^c   Slade, Herbert B ^c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c 3M COMPANY   (United States)

Author keywords

Aldara(TM); Condylomata acuminata; Cytokine; Human papilloma virus; Imiquimod; Interferon

Indexed keywords

ALPHA INTERFERON; CELL SURFACE MARKER; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 12; MESSENGER RNA; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL CYCLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; KERATINOCYTE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOPICAL DRUG ADMINISTRATION; WART VIRUS;

ADOLESCENT; ADULT; AMINOQUINOLINES; ANTIGENS, CD; CELL DIFFERENTIATION; CELL DIVISION; CONDYLOMATA ACUMINATA; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; INTERFERON INDUCERS; KERATINOCYTES; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; VIRAL LOAD;

EID: 0032802988     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00033-9     Document Type: Article

References (31)

1. Arany I., Rady P., Tyring S.K. Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway. Antiviral Res. 23:1994;131-141.
2. Arany I., Tyring S.K. Status of local cellular immunity in interferon-responsive and non-responsive human papillomavirus-associated lesions. Sex. Transm. Dis. 23:1996;475-480.
3. Arany I., Tyring S.K. Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J. Interferon Cytokine Res. 16:1996;453-460.
4. Arany I., Goel A., Tyring S.K. Interferon response depends on viral transcription in human papillomavirus-containing lesions. Anticancer Res. 15:1995;2865-2869.
5. Arany I., Nagamani K., Tyring S.K. Interferon resistance is independent from copy numbers in benign HPV-induced lesions. Anticancer Res. 15:1995;1003-1006.
6. Arany I., Rady P., Tyring S.K. Effect of interferon therapy on human papillomavirus copy number in patients with condyloma acuminatum. Am. J. Med. Sci. 310:1995;14-18.
7. Becker T.M., Stone K.M., Alexander E.R. Genital human papillomavirus infection. A growing concern. Obstet. Gynecol. Clin. North Am. 14:1987;389-396.
8. Bernstein D.I., Harrison C.J. Effects of the immunomodulating agent R-837 on acute and latent herpes simplex virus type 2 infections. Antimicrob. Agents Chemother. 33:1989;1511-1515.
9. Bernstein D.I., Miller R.L., Harrison C.J. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J. Infect. Dis. 167:1993;731-735.
10. Beutner K.R., Tyring S.K., Trofatter K.P. Imiquimod, a patient-applied immune response modifier for treatment of external genital warts. Antimicrob. Agents Chemother. 42:1998;789-794.
11. Bishop P.E., McMillan A., Fletcher S. An immunohistological study of spontaneous regression of condylomata acuminata. Genitourin. Med. 66:1990;79-81.
12. Coleman N., Birley H.D.L., Renton A.M. et al. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102:1994;768-774.
13. Edwards L., Ferenczy A., Eron L., Baker D., Owens M., Fox T., Hougham A., Schmitt K. Self administered topical 5% imiquimod cream for external anogenital warts. Arch. Dermatol. 134:1998;25-30.
14. Harrison C.J., Jenski L., Voychehovski T., Bernstein D.I. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res. 10:1988;209-223. (published erratum appears in Antiviral Res. 11, 215, 1989).
15. Harrison C.J., Miller R.L., Bernstein D.I. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. 38:1994;2059-2064.
16. Imbertson L.M., Beaurline J.M., Couture A.M., Gibson S.J., Smith R.M., Miller R.L., Reiter M.J., Wagner T.L., Tomai M.A. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifier's imiquimod and S-28463. J. Invest. Dermatol. 110:1998;101-106.
17. Kono T., Kondo S., Pastore S. et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. 13:1994;71-76.
18. Koutsky L.A., Galloway D.A., Holmes K.K. Epidemiology of genital human papillomavirus infection. Epidemiol. Rev. 10:1988;122-163.
19. Kraus S.J., Stone K.M. Management of genital infection caused by human papillomavirus. Rev. Infect. Dis. 12:1990;S620-S632.
20. Megyeri K., Au W.C., Rosztoczy I. et al. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol. Cell. Biol. 15:1995;2207-2218.
21. Parronchi P.M., De Carli R., Manetti C. et al. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J. Immunol. 149:1992;2977-2983.
22. Rady P.L., Chin R., Arany I., Hughes T.K., Tyring S.K. Direct sequencing of consensus primer generated PCR fragments of human papillomaviruses. J. Virol. Methods. 43:1993;335-350.
23. Reiter M.J., Testerman T.L., Miller R.L., Weeks C.E., Tomai M.A. Cytokine induction in mice by the immunomodulator imiquimod. J. Leukocyte Biol. 55:1994;234-240.
24. + T cells. J. Clin. Invest. 97:1996;309-315.
25. Sidky Y.A., Borden E.C., Weeks C.E., Reiter M.J., Hatcher J.F., Bryan G.T. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 52:1992;3528-3533.
26. Slade H.B., Owens M.L., Tomai M.A., Miller R.L. Imiquimod 5% cream (Aldara™). Exp. Opin. Invest. Drugs. 7:1998;437-449.
27. Stone K.M. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin. Infect. Dis. 20:1995;91-97.
28. Testerman T.L., Gerster J.F., Imberston L.M. et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukocyte Biol. 58:1995;365-372.
29. Tomai M.A., Birmachu W., Case M.T. et al. Imiquimod: in vivo and in vitro characteristics and toxicology. Aly R., Beutner K.R., Maibach H. Cutaneous Infection and Therapy. 1997;405-415 Marcel Dekker, New York.
30. Tyring S.K., Arany I., Stanley M.A. et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis. 178:1998;551-555.
31. Wagner T.L., Ahonen C.L., Couture A.M. et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191:1999;10-19.